USFDA issues 1 observation to Everest Organics Aroor facility
New Delhi : Pharma firm Everest Organics said that the US health regulator inspected its Aroor plant and has made one observation.
"The United States Food and Drug Administration (USFDA) inspected our facility at village Aroor from February 27, 2017 to March 3, 2017. There is only one observation," Everest Organics said in a filing to BSE.
The company believes that this is of minor nature and corrective and preventive action for this observation will be presented to the regulator shortly, it added.
Everest Organics develops, manufactures and markets a broad range of APIs and bulks drugs intermediates. It exports the products to over 20 countries.
Shares of Everest Organics were today trading 4.84 per cent higher at Rs 72.60 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd